Research Analysts Offer Predictions for FHTX Q1 Earnings

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a report issued on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.34) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($1.34) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.13. The firm had revenue of $2.86 million for the quarter, compared to analysts’ expectations of $8.56 million.

A number of other research analysts have also issued reports on the company. Jefferies Financial Group decreased their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $13.17.

Foghorn Therapeutics Stock Up 3.8 %

FHTX opened at $4.60 on Monday. Foghorn Therapeutics has a 52 week low of $3.86 and a 52 week high of $10.25. The business has a fifty day simple moving average of $4.69 and a 200-day simple moving average of $6.56. The firm has a market cap of $255.82 million, a P/E ratio of -2.40 and a beta of 3.13.

Institutional Trading of Foghorn Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FHTX. Hsbc Holdings PLC increased its position in Foghorn Therapeutics by 12.4% in the 4th quarter. Hsbc Holdings PLC now owns 18,728 shares of the company’s stock valued at $88,000 after acquiring an additional 2,061 shares during the period. Sherbrooke Park Advisers LLC increased its position in Foghorn Therapeutics by 22.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 15,617 shares of the company’s stock worth $74,000 after purchasing an additional 2,841 shares during the period. Northern Trust Corp increased its position in Foghorn Therapeutics by 1.1% during the 4th quarter. Northern Trust Corp now owns 253,671 shares of the company’s stock worth $1,197,000 after purchasing an additional 2,873 shares during the period. Rhumbline Advisers increased its position in Foghorn Therapeutics by 9.1% during the 4th quarter. Rhumbline Advisers now owns 36,384 shares of the company’s stock worth $172,000 after purchasing an additional 3,049 shares during the period. Finally, Wells Fargo & Company MN increased its position in Foghorn Therapeutics by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 15,841 shares of the company’s stock worth $75,000 after purchasing an additional 3,958 shares during the period. Institutional investors and hedge funds own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.